Current chemotherapeutic options for the treatment of gestational trophoblastic disease

References

• Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717–729.
   PubMed Web of Science ®Google Scholar
• Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11–18.
   PubMed Web of Science ®Google Scholar
• Braga A, Mora P, de Melo AC, et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol. 2019;10(2):28–37.
   PubMed Web of Science ®Google Scholar
• Biscaro A, Braga A, Berkowitz RS. Diagnosis, classification and treatment of gestational trophoblastic neoplasia. Rev Bras Ginecol Obstet. 2015;37(1):42–51.
   PubMedGoogle Scholar
• Lok C, van Trommel N, Massuger L, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020;130:228–240.
   PubMed Web of Science ®Google Scholar
• Clark JJ, Slater S, Seckl MJ. Treatment of gestational trophoblastic disease in the 2020s. Curr Opin Obstet Gynecol. 2021;33(1):7–12.
   PubMed Web of Science ®Google Scholar
• Elias KM, Berkowitz RS, Horowitz NS. State-of-the-art workup and initial management of newly diagnosed molar pregnancy and postmolar gestational trophoblastic neoplasia. J Natl Compr Canc Netw. 2019;17(11):1396–1401.
   PubMed Web of Science ®Google Scholar
• Maestá I, Braga A. Challenges of the treatment of patients with gestational trophoblastic disease. Rev Bras Ginecol Obstet. 2012;34(4):143–146.
   PubMedGoogle Scholar
• Freitas F, Braga A, Viggiano M, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: a retrospective national cohort study. Gynecol Oncol. 2020;158(2):452–459.
   PubMed Web of Science ®Google Scholar
• Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi39–50.
   PubMed Web of Science ®Google Scholar
• Braga A, Moraes V, Maestá I, et al. Changing trends in the clinical presentation and management of complete hydatidiform mole among Brazilian women. Int J Gynecol Cancer. 2016;26(5):984–990.
   PubMed Web of Science ®Google Scholar
• Sun SY, Melamed A, Goldstein DP, et al. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol. 2015;138(1):46–49.
   PubMed Web of Science ®Google Scholar
• Padrón L, Rezende Filho J, Amim Junior J, et al. Manual compared with electric vacuum aspiration for treatment of molar pregnancy. Obstet Gynecol. 2018;131(4):652–659.
   PubMed Web of Science ®Google Scholar
• Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017;9(9):CD007289.
   PubMedGoogle Scholar
• FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO oncology committee. Int J Gynaecol Obstet. 2002;77(3):285–287.
   PubMed Web of Science ®Google Scholar
• Giorgione V, Bergamini A, Cioffi R, et al. Role of Surgery in the management of hydatidiform mole in elderly patients: a single-center clinical experience. Int J Gynecol Cancer. 2017;27(3):550–553.
   PubMed Web of Science ®Google Scholar
• Zhao P, Lu Y, Huang W, et al. Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):13.
   PubMedGoogle Scholar
• Elias KM, Shoni M, Bernstein M, et al. Complete hydatidiform mole in women aged 40 to 49 years. J Reprod Med. 2012;57(5–6):254–258.
   PubMed Web of Science ®Google Scholar
• Elias KM, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women older than age 50. J Reprod Med. 2010;55(5–6):208–212.
   PubMed Web of Science ®Google Scholar
• Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(S1):86–93.
   PubMedGoogle Scholar
• Souza JMQ, Braga A, Sanches Dos Santos R, et al. Comparison of 2 human chorionic gonadotropin immunoassays commercially available for monitoring patients with gestational trophoblastic disease. Int J Gynecol Cancer. 2017;27:1494–1500.
   PubMed Web of Science ®Google Scholar
• Braga A, Maestá I, Short D, et al. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review. Bjog. 2016;123(8):1330–1335.
   PubMed Web of Science ®Google Scholar
• Dantas PRS, Maestá I, Filho JR, et al. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Gynecol Oncol. 2017;147(2):364–370.
   PubMed Web of Science ®Google Scholar
• Braga A, Elias KM, Horowitz NS, et al. When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia. Br J Cancer. 2021;124(6):1033–1034.
   PubMed Web of Science ®Google Scholar
• Parker VL, Winter MC, Whitby E, et al. Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia. Br J Cancer. 2021;124(6):1066–1071.
   PubMed Web of Science ®Google Scholar
• Mapelli P, Mangili G, Picchio M, et al. Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging. 2013;40(4):505–513.
   PubMed Web of Science ®Google Scholar
• Bezzi C, Monaco L, Ghezzo S, et al. 18F-FDG PET/CT may predict tumor type and risk score in gestational trophoblastic disease. Clin Nucl Med. 2022;47(6):525–531.
   PubMed Web of Science ®Google Scholar
• Lima LLA, Parente RC, Maestá I, et al. Clinical and radiological correlations in patients with gestational trophoblastic disease. Radiol Bras. 2016;49(4):241–250.
   PubMedGoogle Scholar
• Winter MC. Treatment of low-risk gestational trophoblastic neoplasia. Best Pract Res Clin Obstet Gynaecol. 2021;74:67–80.
   PubMed Web of Science ®Google Scholar
• Dantas PR, Maestá I, Cortés-Charry R, et al. Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study. J Reprod Med. 2012;57(7–8):305–309.
   PubMed Web of Science ®Google Scholar
• Braga A, Elias KM, Horowitz NS, et al. Challenges in the treatment of low-risk gestational trophoblastic neoplasia. Rev Bras Ginecol Obstet. 2021;43:503–506.
   PubMedGoogle Scholar
• Abu-Rustum NR, Yashar CM, Bean S, et al. Gestational trophoblastic neoplasia,version 2.2019,NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(11):1374–1391.
   PubMed Web of Science ®Google Scholar
• Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol. 2004;95(3):423–429.
   PubMedGoogle Scholar
• van Trommel NE, Massuger LF, Verheijen RH, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005;99(1):6–13.
   PubMedGoogle Scholar
• Osborne RJ, Filiaci VL, Schink JC, et al. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol. 2016;128(3):535–542.
   PubMed Web of Science ®Google Scholar
• Bolze PA, Mathe M, Hajri T, et al. First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive. Gynecol Oncol. 2018;150(2):282–287.
   PubMed Web of Science ®Google Scholar
• Berkowitz RS, Horowitz NS, Elias KM. Initial management of low-risk gestational trophoblastic neoplasia. In: Goff B, Dizon DS, editors. Wolters Kluwer. Waltham (MA): UpToDate Inc; 2021 Nov 29. [cited 2022 May 20]. Available from: https://www.uptodate.com/contents/initial-management-of-high-risk-gestational-trophoblastic-neoplasia
   Google Scholar
• Lawrie TA, Alazzam M, Tidy J, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;2016(6):CD007102.
   PubMedGoogle Scholar
• Uberti EM, Fajardo MC, Cunha AG, et al. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women. Rev Bras Ginecol Obstet. 2015;37(6):258–265.
   PubMedGoogle Scholar
• Schink JC, Filiaci V, Huang HQ, et al. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low-risk gestational trophoblastic neoplasia; NRG/GOG 275. Gynecol Oncol. 2020;158(2):354–360.
   PubMed Web of Science ®Google Scholar
• Maestá I, Nitecki R, Horowitz NS, et al. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England trophoblastic disease center experience. Gynecol Oncol. 2018;148(1):161–167.
   PubMed Web of Science ®Google Scholar
• Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the charing cross hospital, 2000-2009. Br J Cancer. 2012;107(11):1810–1814.
   PubMed Web of Science ®Google Scholar
• Mangili G, Cioffi R, Danese S, et al. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. Gynecol Oncol. 2018;151(3):449–452.
   PubMed Web of Science ®Google Scholar
• Soper JT, Clarke-Pearson DL, Berchuck A, et al. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol. 1994;54(1):76–79.
   PubMed Web of Science ®Google Scholar
• Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol. 1995;172(2):574–579.
   PubMed Web of Science ®Google Scholar
• Braga A, Souza CHA, Mora PAR, et al. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. Gynecol Oncol. 2020;156(3):598–605.
   PubMed Web of Science ®Google Scholar
• Bagshawe KD, Dent J, Newlands ES, et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol. 1989;96(7):795–802.
   PubMedGoogle Scholar
• Goldstein DP, Berkowitz RS, Horowitz NS. Optimal management of low-risk gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2015;15(11):1293–1304.
   PubMed Web of Science ®Google Scholar
• Poli JG, Paiva G, Freitas F, et al. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right? Gynecol Oncol. 2021;162(3):638–644.
   PubMed Web of Science ®Google Scholar
• Braga A, Paiva G, Ghorani E, et al. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(8):1188–1198.
   PubMed Web of Science ®Google Scholar
• Maestá I, Nitecki R, Desmarais CCF, et al. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2020;157(2):372–378.
   PubMed Web of Science ®Google Scholar
• Cortés-Charry R, Hennah L, Froeling FEM, et al. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy. ESMO Open. 2021;6(3):100110.
   PubMed Web of Science ®Google Scholar
• Winter MC, Tidy JA, Hills A, et al. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2016;143(3):565–570.
   PubMed Web of Science ®Google Scholar
• Mora PAR, Sun SY, Velarde GC, et al. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol. 2019;153(2):277–285.
   PubMed Web of Science ®Google Scholar
• Bolze PA, Patrier S, Massardier J, et al. PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer. 2017;27(3):554–561.
   PubMed Web of Science ®Google Scholar
• You B, Bolze PA, Lotz JP, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN Phase II trial. J Clin Oncol. 2020;38(27):3129–3137.
   PubMed Web of Science ®Google Scholar
• Mangili G, Sabetta G, Cioffi R, et al. Current evidence on immunotherapy for gestational trophoblastic neoplasia (GTN). Cancers (Basel). 2022;14(11):2782.
   PubMed Web of Science ®Google Scholar
• Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 2021;137(2):355–370. Erratum in: Obstet Gynecol 139(1), 149 (2022).
   PubMed Web of Science ®Google Scholar
• Salman L, Bouchard-Fortier G, Covens A, et al. Immune checkpoint inhibitors for the treatment of gestational trophoblastic neoplasia: rationale, effectiveness, and future fertility. Curr Treat Options Oncol. 2022;23(7):1035–1043.
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol. 1997;15(7):2636–2643.
   PubMed Web of Science ®Google Scholar
• Matsui H, Suzuka K, Iitsuka Y, et al. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol. 2000;78(1):28–31.
   PubMed Web of Science ®Google Scholar
• Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med. 2006;51(10):767–772.
   PubMed Web of Science ®Google Scholar
• Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. J Reprod Med. 2012;57(5–6):231–236.
   PubMed Web of Science ®Google Scholar
• Kanis MJ, Greendyk R, Sobecki-Rausch J, et al. Use of granulocyte colony stimulating factors (G-CSFs) with multiagent chemotherapy for gestational trophoblastic neoplasia (GTN). Gynecol Oncol. 2017;145:218.
   Web of Science ®Google Scholar
• Jareemit N, Horowitz NS, Goldstein DP, et al. EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. Gynecol Oncol. 2020;158(1):99–104.
   PubMed Web of Science ®Google Scholar
• Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med. 2002;47(6):465–471.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21:1471–1482.
   PubMed Web of Science ®Google Scholar
• Herrington S. Enhancing cure and palliation: radiation therapy in the treatment of metastatic gestational trophoblastic neoplasia. Semin Oncol. 1995;22(2):185–192.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Newlands ES, Begent RH, et al. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol. 1989;7(7):900–903.
   PubMed Web of Science ®Google Scholar
• Savage P, Kelpanide I, Tuthill M, et al. Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol. 2015;137(1):73–76.
   PubMed Web of Science ®Google Scholar
• Savage PM, Yang X, Yang J, et al. CNS metastases in GTN. An update on demographics, diagnosis and management. In: Hancock BW, Seckl MJ, Berkowitz RS, editors. Gestational trophoblastic disease. 5th ed. London: ISSTD 2022; p. 1–18. Chapter 18. [cited 2022 Oct 14]. Available from: https://isstd.org/uploadedfiles/18cnsjs.pdf
   Google Scholar
• Gavanier D, Leport H, Massardier J, et al. Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study. Int J Clin Oncol. 2019;24(2):153–160.
   PubMed Web of Science ®Google Scholar
• Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017;390(10110):2343–2345.
   PubMed Web of Science ®Google Scholar
• Yang J, Xiang Y, Wan X, et al. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): a report based on our 10-year clinical experiences. Gynecol Oncol. 2016;143(1):68–72.
   PubMed Web of Science ®Google Scholar
• Maesta I, Moreira MFS, Rezende-Filho K, et al. Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. Int J Gynecol Cancer. 2020;30(9):1366–1371.
   PubMed Web of Science ®Google Scholar
• Deng L, Zhang J, Wu T, et al. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev. 2013;1:CD005196.
   PubMedGoogle Scholar
• Lybol C, Thomas CMG, Blanken EA, et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer. 2013;49(4):860–867.
   PubMed Web of Science ®Google Scholar
• Osborne R, Covens A, Mirchandani D, et al. Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet. J Reprod Med. 2004;49(8):655–661.
   PubMed Web of Science ®Google Scholar
• Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol. 2008;19(9):1578–1583.
   PubMed Web of Science ®Google Scholar
• Matsui H, Suzuka K, Iitsuka Y, et al. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer. 2002;95(5):1051–1054.
   PubMed Web of Science ®Google Scholar
• Wang PH, Yuan CC, Chao HT, et al. The VIP regimen effective treatment to refractory choriocarcinoma: a case report. Zhonghua Yi Xue Za Zhi (Taipei). 1997;59(5):320–324
   PubMedGoogle Scholar
• Clark J, Suyanto S, Hennah L, et al. 807P Multi-centre study of escalated etoposide/cisplatin (Esc-EP) as a novel salvage regimen in advanced/refractory gestational trophoblastic neoplasia. Ann Oncol. 2021;32(S5):S765.
   Google Scholar
• Frijstein MM, Lok CAR, Short D, et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Cancer. 2019;109:162–171.
   PubMed Web of Science ®Google Scholar
• Yamamoto E, Niimi K, Fujikake K, et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: a case report and literature review. Mol Clin Oncol. 2016;5(5):660–664.
   PubMedGoogle Scholar
• Bolze PA, Riedl C, Massardier J, et al. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13. Am J Obstet Gynecol. 2016;214(3):390.e1–8.
   PubMed Web of Science ®Google Scholar
• Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31(2):280–286.
   PubMed Web of Science ®Google Scholar
• Patel SM, Arora R, Tiwari R, et al. Management of “ultra-high risk” gestational trophoblastic neoplasia at a tertiary center in India. Indian J Med Paediatr Oncol. 2020;41:345–350.
   Web of Science ®Google Scholar
• Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2006;51(10):773–776.
   PubMed Web of Science ®Google Scholar
• Eysbouts YK, Massuger LFAG, IntHout J, et al. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecol Oncol. 2017;145(3):536–542.
   PubMed Web of Science ®Google Scholar
• Silva ACBD, Passos JP, Signorini Filho RC, et al. Uterine rescue in high-risk gestational trophoblastic neoplasia treated with EMA-CO by uterine arteries embolization due to arteriovenous malformations. Rev Bras Ginecol Obstet. 2021;43:323–328.
   PubMedGoogle Scholar
• You B, Bolze P, Lotz J, et al. 273 Avelumab in patients with gestational trophoblastic tumors resistant to polychemotherapy: efficacy outcomes of cohort B of TROPHIMMUN phase II trial. Int J Gyncol Cancer. 2021;31:A344.
   Web of Science ®Google Scholar
• Cheng H, Zong L, Kong Y, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2021;22(11):1609–1617.
   PubMed Web of Science ®Google Scholar
• Elias KM, Braga A, Horowitz NS, et al. A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. Lancet Oncol. 2021;22(11):1490–1491.
   PubMed Web of Science ®Google Scholar
• Newlands ES, Bower M, Fisher RA, et al. Management of placental site trophoblastic tumors. J Reprod Med. 1998;43:53–59.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lv WG, Feng FZ, et al. Placental site trophoblastic tumor: a review of 108 cases and their implications for prognosis and treatment. Gynecol Oncol. 2016;142(1):102–108.
   PubMed Web of Science ®Google Scholar
• Davis MR, Howitt BE, Quade BJ, et al. Epithelioid trophoblastic tumor: a single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol. 2015;137(3):456–461.
   PubMed Web of Science ®Google Scholar
• Frijstein MM, Lok CAR, van Trommel NE, et al. Management and prognostic factors of epithelioid trophoblastic tumors: results from the international society for the study of trophoblastic diseases database. Gynecol Oncol. 2019;152(2):361–367.
   PubMed Web of Science ®Google Scholar
• Horowitz NS, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: biology, natural history, and treatment modalities. Gynecol Oncol. 2017;144:208–214.
   PubMed Web of Science ®Google Scholar
• Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet. 2009;374(9683):48–55.
   PubMed Web of Science ®Google Scholar
• Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;96(5):732–737.
   PubMed Web of Science ®Google Scholar
• Porter A, Barcelon JM, Budker RL, et al. Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate. Gynecol Oncol Rep. 2021;36:100782.
   PubMed Web of Science ®Google Scholar
• Froeling FEM, Ramaswami R, Papanastasopoulos P, et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer. 2019;120(6):587–594.
   PubMed Web of Science ®Google Scholar
• Alazzam M, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;2016(1):CD008891.
   PubMedGoogle Scholar
• Balachandran K, Salawu A, Ghorani E, et al. When to stop human chorionic gonadotropin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): a national analysis on over 4,000 patients. Gynecol Oncol. 2019;155(1):8–12.
   PubMed Web of Science ®Google Scholar
• Elias KM, Berkowitz RS, Horowitz NS. Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: when is enough enough? Gynecol Oncol. 2019;155(1):1–2.
   PubMed Web of Science ®Google Scholar
• Savage P, Cooke R, O’Nions J, et al. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol. 2015;33(5):472–478.
   PubMed Web of Science ®Google Scholar
• Madi JM, Paganella MP, Litvin IE, et al. Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysis. Am J Obstet Gynecol. 2022;226(5):633–645.
   PubMed Web of Science ®Google Scholar
• Braga A, Maestá I, Michelin OC, et al. Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women. Gynecol Oncol. 2009;112(3):568–571.
   PubMed Web of Science ®Google Scholar
• Joneborg U, Coopmans L, van Trommel N, et al. Fertility and pregnancy outcome in gestational trophoblastic disease. Int J Gynecol Cancer. 2021;31(3):399–411.
   PubMed Web of Science ®Google Scholar
• Cioffi R, Bergamini A, Gadducci A, et al. Reproductive outcomes after gestational trophoblastic neoplasia. A comparison between single-agent and multiagent chemotherapy: retrospective analysis from the MITO-9 group. Int J Gynecol Cancer. 2018;28(2):332–337.
   PubMed Web of Science ®Google Scholar
• Wenzel L, Berkowitz RS, Newlands E, et al. Quality of life after gestational trophoblastic disease. J Reprod Med. 2002;47(5):387–394.
   PubMed Web of Science ®Google Scholar
• Ireson J, Jones G, Winter MC, et al. Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach. Lancet Oncol. 2018;19(1):e56–e64.
   PubMed Web of Science ®Google Scholar
• França ACG, Uberti EMH, Muller KP, et al. Emotional and clinical aspects observed in women with gestational trophoblastic disease: a multidisciplinary action. Rev Bras Ginecol Obstet. 2022;44:343–351.
   PubMedGoogle Scholar
• Ferreira EG, Maestá I, Michelin OC, et al. Assessment of quality of life and psychologic aspects in patients with gestational trophoblastic disease. J Reprod Med. 2009;54(4):239–244.
   PubMed Web of Science ®Google Scholar
• Diniz MV, Sun SY, Barsottini C, et al. Experience with the use of an online community on Facebook for Brazilian patients with gestational trophoblastic disease: netnography study. J Med Internet Res. 2018;20(9):e10897.
   PubMed Web of Science ®Google Scholar